A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Canc

Protocol No

LILLY-J3M-MC-JZQH

Staff Member

Hui-Zi Chen

Phase

III

Summary

Study of olomorasib combined with SOC immunotherapy for KRAS G12C-mutant NSCLC

Objective

This study aims to determine the efficacy of olomorasib in combination with standard of care immunotherapy following definitive NSCLC therapy.

Status

SRC APPROVAL

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02